IFNA1 and systemic lupus erythematosus: In NZB/W F1 mice susceptible to lupus, continuous in vivo administration of adenovector-derived murine IFN-α resulted in enhanced clinical disease and IFN signaling (Mathian et al., 2005; Liu et al., 2011).